Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

on activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the SEC. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended March 31, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... NY (PRWEB) August 29, 2014 Local ... Hills Veterinary Hospital are seeking candidates to participate in ... with osteoarthritis. The ultimate goal of this study ... stem cells into one or two arthritically affected joints ... joints. , Candidates for the current investigational study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
(Date:8/28/2014)... A new research platform uses a laser ... structures undergoing stress and heating, an approach ... for microelectronics and batteries., This new technique, ... how heating and the surface stress of ... have discussed the merits of surface-stress influence ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
... TRIANGLE PARK, N.C., Nov. 16, 2010 Scientists ... data demonstrating that the company,s lipid-conjugated drugs, ... human Organic Anion Transporters (hOATs) and thus have ... mechanism.  These data, presented at the International Pharmaceutical ...
... American presence ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Intel Corporation acquires Toronto start-up CognoVision 2Intel Corporation acquires Toronto start-up CognoVision 3Intel Corporation acquires Toronto start-up CognoVision 4Intel Corporation acquires Toronto start-up CognoVision 5Intel Corporation acquires Toronto start-up CognoVision 6Intel Corporation acquires Toronto start-up CognoVision 7Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4Enerkem adds two new executive roles to growing North American presence 2Enerkem adds two new executive roles to growing North American presence 3Enerkem adds two new executive roles to growing North American presence 4Enerkem adds two new executive roles to growing North American presence 5Enerkem adds two new executive roles to growing North American presence 6Enerkem adds two new executive roles to growing North American presence 7
(Date:8/29/2014)... of marine phytoplankton, such as the prolific bloomer ... (thiamine), researchers have discovered. The finding contradicts the common ... eukaryotic microbes depend on scarce supplies of thiamine in ... way to think about the ocean," says CIFAR Senior ... ISME Journal paper with CIFAR fellows John ...
(Date:8/28/2014)... Entomological Society of America (ESA) is pleased to announce ... Member of the Society. Honorary Membership acknowledges those who ... significant involvement in the affairs of the Society that ... are selected by the ESA Governing Board and then ... be honored at the Awards Ceremony at Entomology 2014, ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... evidence that Parkinson,s disease may have an infectious or ... is associated with late-onset sporadic Parkinson,s disease" appears online ... conducted by the NeuroGenetics Research Consortium, an international team ... the New York State Department of Health Wadsworth Center. ...
... State University have developed a method for predicting the ... the human body. Their work could have implications for ... of nanomaterials, as well as applications for drug delivery. ... Distinguished Professor of Pharmacology and director of the ...
... SALT LAKE CITY, July 26 Wall Street Communications ... Media, a world leader in content identification solutions, to ... a presence for the company in broadcast, government, and ... Media, based in Darmstadt, Germany, is a spinoff of ...
Cached Biology News:Researchers discover genetic link between immune system, Parkinson's disease 2Probing the nanoparticle: Predicting how nanoparticles will react in the human body 2Wall Street Communications Retained by iPharro Media 2
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
...
... Immunogen: Synthetic Peptide: M(1) E F ... G P P T M D L E(19) ... mouse cells.,PA1-072 has been successfully used in Western ... detects an ~86 kDa protein representing Mint3 from ...
... (AR) Competitor Assay Kits provide a sensitive ... potential AR ligands using fluorescence polarization (FP). ... domain protein tagged with His and GST ... androgen ligand (Fluormone AL Green in the ...
Biology Products: